Health Care & Life Sciences » Biotechnology | Orexigen Therapeutics Inc.

Orexigen Therapeutics Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2012
2013
2014
2015
2016
Sales/Revenue
3,428.00
3,428.00
55,521.00
24,459.00
33,709.00
Cost of Goods Sold (COGS) incl. D&A
-
94.00
-
223.00
11,302.00
Gross Income
-
3,334.00
-
24,236.00
22,407.00
SG&A Expense
93,354.00
80,532.00
85,912.00
84,289.00
156,606.00
EBIT
90,239.00
77,198.00
30,530.00
-
134,199.00
Unusual Expense
-
-
-
-
120,916.00
Non Operating Income/Expense
-
-
-
39.00
3,880.00
Interest Expense
2.00
538.00
7,083.00
7,446.00
7,850.00
Pretax Income
90,094.00
77,671.00
37,525.00
67,311.00
24,391.00
Income Tax
-
-
-
1,376.00
133.00
Consolidated Net Income
90,094.00
77,671.00
37,525.00
68,687.00
24,524.00
Net Income
90,094.00
77,671.00
37,525.00
68,687.00
24,524.00
Net Income After Extraordinaries
90,094.00
77,671.00
37,525.00
68,687.00
24,524.00
Net Income Available to Common
90,094.00
77,671.00
37,525.00
68,687.00
24,524.00
EPS (Basic)
12.74
8.05
3.17
52.40
1.68
Basic Shares Outstanding
7,073.90
9,649.10
11,824.00
1,311.30
14,576.00
EPS (Diluted)
12.74
8.05
3.17
52.38
1.68
Diluted Shares Outstanding
7,073.90
9,649.10
11,824.00
1,311.30
14,576.00
EBITDA
89,926.00
77,104.00
30,391.00
59,830.00
130,464.00
Non-Operating Interest Income
147.00
65.00
88.00
227.00
622.00

About Orexigen Therapeutics

View Profile
Address
3344 North Torrey Pines Court
La Jolla California 92037
United States
Employees -
Website http://www.orexigen.com
Updated 09/14/2018
Orexigen Therapeutics, Inc. is a biopharmaceutical company, which focuses on the development of pharmaceutical product candidates for the treatment of obesity. Its primary activities includes recruiting personnel, conducting research and development, including clinical trials, raising capital and preparing for the marketing and commercialization of its product, contrave. The company was founded by Eckard Weber in September 2002 and is headquartered in La Jolla, CA.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.